Sign up
Pharma Capital

Sensyne Health signs exclusive licence agreement for a digital health software product, Support-HF

The Oxford-based firm said Support-HF will help patients and clinicians in managing heart failure and curate data for medical research using Clinical AI
AI
Sensyne said it also plans to develop a cloud-based scalable version of Support-HF

Sensyne Health Ltd, which is set to list on AIM on August 17, said on Wednesday that it has signed an exclusive licence agreement for a digital health software product, Support-HF, with the University of Oxford and Oxford University Hospitals NHS Foundation Trust.

The Oxford-based firm, which uses artificial intelligence (AI) to develop medicines said Support-HF will help patients and clinicians in managing heart failure and curate data for medical research using Clinical AI.

READ: Sensyne Health planning to raise £60mln via AIM IPO, according to founder Paul Drayson

The company said it also plans to develop a cloud-based scalable version of Support-HF to help support the management of heart failure at home.

The collaboration, which was established in July last year, creates a pathway for the commercial development of digital health innovations invented and clinically validated by the University and the Trust, Sensyne said.

In a statement on the group’s website, Sensyne founder and chief executive Paul Drayson commented: "Support HF has the potential to make significant improvements in the care of patients suffering from heart failure and is a further example of the pipeline of digital health innovations coming out of research at Oxford.”

Drayson, a peer and a former Labour government minister in the 2000’s added: "Sensyne Health will now develop the product so that it may be deployed more widely across the NHS and then internationally.”



Register here to be notified of future SENS Company articles
View full SENS profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.